Pembrolizumab as adjuvant therapy for TNBC

KEYNOTE-522: Neoadjuvant and adjuvant pembrolizumab for early TNBC

KEYNOTE-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...

Neoadjuvant and adjuvant therapy in triple negative breast cancer

What to do in patients with early-stage TNBC who have not achieved a pCR?

Neoadjuvant Versus Adjuvant Therapy in TNBC

ASCO: Pembrolizumab Plus Chemotherapy for Advanced Triple-Negative Breast Cancer

The challenges of treating early-stage TNBC

KEYNOTE-355: pembrolizumab in triple-negative breast cancer

Emerging immunotherapy beyond checkpoint inhibitors for TNBC

New directions in immunotherapy for improving outcomes in TNBC

Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early triple-negative breas...

Pathologic complete response rates improved with the neoadjuvant and adjuvant treatment of pembr...

De-escalation of therapy in early-stage TNBC

Optimal neoadjuvant and adjuvant therapy for patients with early TNBC

A post hoc analysis of adjuvant radiation therapy in the KEYNOTE-522 study

Tailoring neoadjuvant and adjuvant therapy in TNBC

Dr. Sara Tolaney on Eribulin Plus Pembrolizumab for Metastatic Triple-Negative Breast Cancer

Atezolizumab With Adjuvant Chemotherapy for Early-Stage Triple Negative Breast Cancer